Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Cash & Equivalents (2021 - 2024)

Opus Genetics (IRD) has disclosed Cash & Equivalents for 8 consecutive years, with $42.4 million as the latest value for Q3 2023.

  • On a quarterly basis, Cash & Equivalents rose 205.67% to $42.4 million in Q3 2023 year-over-year; TTM through Sep 2023 was $42.4 million, a 205.67% increase, with the full-year FY2022 number at $42.6 million, up 73.78% from a year prior.
  • Cash & Equivalents was $42.4 million for Q3 2023 at Opus Genetics, up from $40.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $42.6 million in Q4 2022 to a low of $10.6 million in Q1 2021.
  • A 3-year average of $26.9 million and a median of $24.2 million in 2021 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 37.73% in 2022, then soared 205.67% in 2023.
  • Opus Genetics' Cash & Equivalents stood at $24.5 million in 2021, then surged by 73.78% to $42.6 million in 2022, then fell by 0.67% to $42.4 million in 2023.
  • Per Business Quant, the three most recent readings for IRD's Cash & Equivalents are $42.4 million (Q3 2023), $40.0 million (Q2 2023), and $39.0 million (Q1 2023).